Welcome to our dedicated page for Solid Bioscience news (Ticker: SLDB), a resource for investors and traders seeking the latest updates and insights on Solid Bioscience stock.
Solid Biosciences Inc. (SLDB) is a precision genetic medicine company whose news flow centers on the development of gene therapy candidates for rare neuromuscular and cardiac diseases. Company announcements highlight progress across multiple clinical programs, regulatory designations and collaborations related to its investigational therapies and platform technologies.
Investors and observers following SLDB news can expect updates on key clinical trials such as INSPIRE DUCHENNE and IMPACT DUCHENNE for SGT-003 in Duchenne muscular dystrophy, the FALCON Phase 1b trial of SGT-212 in Friedreich’s ataxia, and the ARTEMIS Phase 1b trial of SGT-501 for catecholaminergic polymorphic ventricular tachycardia. News items also describe interim clinical data, including safety, tolerability, biomarker changes and cardiac monitoring findings, as well as regulatory interactions and designations from agencies such as the U.S. Food and Drug Administration and U.K. authorities.
Solid Biosciences’ news releases additionally cover its proprietary AAV-SLB101 capsid platform, including data presentations at scientific meetings and licensing agreements with partners such as Andelyn Biosciences. Corporate updates, inducement equity grants under Nasdaq Listing Rule 5635(c)(4), and participation in industry conferences like the J.P. Morgan Healthcare Conference also appear in the company’s news record.
This news page aggregates these disclosures so readers can review clinical milestones, regulatory developments, platform collaborations and corporate events related to Solid Biosciences and its SLDB stock over time.
Solid Biosciences Inc. (Nasdaq: SLDB) has announced a change to its 2020 Annual Meeting of Stockholders, which will now be held virtually on June 16, 2020, at 8:00 a.m. Eastern Time due to COVID-19 restrictions. Shareholders who held shares by April 20, 2020, are entitled to participate and vote. Access to the meeting requires a control number from proxy materials. The company emphasizes that all stockholders should vote in advance, and technical support details are provided in a filed proxy supplement.
Solid Biosciences (Nasdaq: SLDB) announced that its IGNITE DMD Phase I/II clinical trial remains on clinical hold by the FDA. In response to the hold, the company submitted a revised clinical protocol in April 2020, focusing on patient safety and manufacturing process improvements. However, the FDA requested further data, which Solid expects to submit by Q3 2020. SGT-001, their gene therapy candidate for Duchenne muscular dystrophy, aims to deliver a synthetic dystrophin gene and has received designations intended to expedite the drug's development.